Aileron was named one of 2009’s “Fierce15” private biotech companies to watch.
|
News & Publications
Press Coverage
 |
By Duff Wilson
The Swiss pharmaceutical giant Roche is throwing its weight behind an experimental technology that could be used to treat a number of diseases. The company has agreed to pay $25 million now and up to $1.1 billion later to Aileron Therapeutics of Cambridge, Mass., for developing a new type of drug technology called "stapled peptides." |
 |
By Marc Wortman
As emerging technologies begin to overcome peptide therapeutics' pharmacologic limitations, their compelling potential grows clearer and their deal value has grown. Most if not all of Big Pharma and Big Biotech now have rebuilt their internal peptide drug development programs and show interest in start-ups with peptide pipelines and platforms. |
 |
By Wendy Wolfson
Aileron Therapeutics is pursuing an innovative drug development platform called stapled peptides that it believes is key to accessing the more than 80% of human targets that are today not reachable by existing biologics or small molecule drugs. The company believes its stapled peptide-based drugs have wide therapeutic potential for cancer, autoimmune, inflammatory, infectious and metabolic diseases. |
 |
By Rob Weisman
Four global pharmaceutical companies have joined in a consortium to provide $40 million in financing to Aileron Therapeutics, a Cambridge biotechnology start-up that is developing a novel approach to treating cancer and other diseases. |
 |
By Tomi K. Sawyer
Aileron's novel Stapled Peptides have unique chemical, biological and structural properties to address both intracellular and extracellular protein-protein interactions that serve as critical control points in disease mechanisms. While such protein-protein interactions have eluded most small-molecule strategies, Aileron's stapled peptides have demonstrated several important properties including efficient cell penetration, high affinity binding to large target protein surfaces, and remarkable metabolic stability and pharmacokinetic properties in vivo. |
 |
By Carmen Drahl
Technology for reinforcing the α-helix, a familiar protein motif throughout biology, could lead to a new class of peptide-based drugs. Because of their particular blend of chemical properties, stabilized helices may work against disease targets that have traditionally been out of reach. |
 |
By Neil Canavan
The time has come for hybrids. For the world of transportation, that means a vehicle that runs on different fuels. For the universe of healthcare, it’s a drug with the properties of more than one vehicle. Both approaches tip their hat to the reality that, like it or not, nature knows best. |
 |
By Mark Hollmer
Cambridge – After spending more than two years as a bare-bones biotechnology company, with just three employees and contract researchers handling all laboratory work, Aileron Therapeutics, Inc. has hired 12 people in the last three months alone. |
 |
By Gail Dutton
Aileron Therapeutics is hot on the trail of a novel drug class that, in animal research, mimics the natural apoptosis process. These stapled alpha-helical peptides actually penetrate cells, allowing them to block intra-cellular protein-protein interactions that can’t be addressed by small molecules or biologics, according to Huw M. Nash, Ph.D., vp, corporate development, in his presentation at Cambridge Healthtech’s “Protein-Protein Interactions as Drug Targets,” held this week in La Jolla, CA. |
|
